Seattle Urology Research Center

Seattle Urology Research Center is a specialized clinical research facility based in Seattle, Washington, dedicated to the advancement of treatments for urological and genitourinary disorders. Led by Medical Director Dr. Jeffrey Frankel, the center serves as a prominent site for Phase 1 through Phase 3 clinical trials, collaborating with global pharmaceutical leaders such as Urovant Sciences, Astellas Pharma, and Ferring Pharmaceuticals. The center has played a pivotal role in the clinical development and regulatory approval of several key therapies, most notably GEMTESA (vibegron) for overactive bladder. SURC provides comprehensive clinical trial services, including patient recruitment, trial management, and data collection, with a primary focus on indications such as prostate cancer, overactive bladder, and stress urinary incontinence. Its contributions to peer-reviewed literature and international urological conferences underscore its status as a leading research hub in the Pacific Northwest.